Inside the US Push to Power the Next Gene Therapy Wave

US groups boost viral vector capacity as demand climbs, raising hopes for steadier gene therapy development

28 Jun 2025

A rise in investment and technical progress is reshaping viral vector manufacturing in the US, marking a shift as gene therapy moves closer to commercial scale. Developers and analysts say the sector is entering a phase in which reliable supply will be central to advancing late-stage programmes.

Demand for viral vectors, the delivery vehicles used in gene therapies, has increased steadily, prompting companies to expand facilities and update production methods. ProBio has opened an integrated site in New Jersey to supply materials for early research and clinical work. Industry analysts view the facility as a notable addition to US capacity as developers seek shorter turnaround times and domestic supply.

Innovation is also advancing. VintaBio has presented data at the 2025 American Society of Gene and Cell Therapy meeting supporting a next-generation manufacturing method designed to improve vector quality and efficiency. While results at commercial scale have yet to be confirmed, the approach has drawn interest for its potential to offer more predictable output.

These moves reflect broader changes in the gene therapy market, which is shifting from research-led activity to a model that requires dependable and scalable production. More programmes are entering late-stage trials, increasing interest in new technology platforms, expanded US manufacturing footprints and partnerships to accelerate growth.

Pressures remain. Rising demand for vectors continues to exceed earlier expectations, and developers face the challenge of expanding capacity while maintaining strict quality standards. Yet industry executives say current investment levels and recent technical gains point to sustained confidence in the long-term outlook for genetic medicines.

Observers are watching how these changes may affect pricing, patient access and development timelines. For now, the expansion of vector capacity is adding momentum to one of biotechnology’s most closely watched sectors.